艾曲泊帕改善单倍体骨髓移植后血小板植入:一项II期研究结果
这项前瞻性II期研究纳入接受骨髓移植物和移植后环磷酰胺预防GVHD的单倍体造血干细胞移植患者,从第+5天起给予艾曲泊帕300 mg/天,主要目标是评估第60天血小板植入(>50 000/μL)。事后分析比较30例艾曲泊帕组与80例对照,第60天植入率分别为73%和50%(p=.043),未观察到艾曲泊帕相关≥4级不良事件。
要点
- 艾曲泊帕组第60天血小板>50 000/μL植入率为73%,对照组为50%(p=.043)。
- 血小板恢复(>20 000/μL)中位时间艾曲泊帕组29天,对照组31天(p=.022)。
- 未观察到艾曲泊帕相关≥4级不良事件。
核心结论
- 总体而言,艾曲泊帕在接受骨髓移植物和移植后环磷酰胺的单倍体造血干细胞移植患者中安全,并改善血小板恢复。
研究设计与样本
- 前瞻性II期研究,纳入年龄≥18岁接受骨髓移植物和移植后环磷酰胺的单倍体造血干细胞移植患者。
- 患者从第+5天起接受艾曲泊帕300 mg/天。
- 主要目标为评估第60天血小板植入(>50 000/μL)。
- 事后分析将患者与未接受艾曲泊帕的同期匹配对照组比较,共纳入110例(艾曲泊帕组30例,对照组80例)。
主要发现
- 艾曲泊帕组73%和对照组50%的患者在第60天达到血小板计数>50 000/μL(p=.043)。
- 未观察到艾曲泊帕相关≥4级不良事件。
- 血小板恢复(>20 000/μL)中位时间艾曲泊帕组29天,对照组31天(p=.022)。
- 血小板恢复(>20 000/μL)累积发生率艾曲泊帕组90%(95%CI:78%-100%),对照组67.5%(95%CI:57%-78%)(p=.014)。
- 血小板输注次数、总生存、无进展生存、GVHD发生率、复发率和非复发死亡率在两组间相似。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Slow platelet recovery frequently occurs after haploidentical hematopoietic stem cell transplantation (haplo-HSCT) with bone marrow graft and post-transplant cyclophosphamide (PCy)-based graft-versus-host disease (GVHD) prophylaxis. Improved platelet recovery may reduce the need for transfusions and improve outcomes. We investigated the safety and efficacy of eltrombopag, a thrombopoietin receptor agonist, at enhancing platelet recovery post-haplo-HSCT. The prospective study included patients ≥18 years of age who received haplo-HSCT with bone marrow graft and PCy. Patients received eltrombopag 300 mg/day starting on Day +5. The primary objective was to estimate platelet engraftment (>50 000/μL by Day 60). In a post hoc analysis, they were compared to a contemporary matched control group who did not receive eltrombopag. One hundred ten patients were included in the analysis (30 eltrombopag and 80 control). Seventy-three percent and 50% of patients in the eltrombopag group and control group, respectively, attained >50 000/μL platelet count by Day 60 (p = .043). No eltrombopag-related grade ≥4 adverse events were observed. Median time to platelet recovery (>20 000/μL) was 29 days with eltrombopag and 31 days for controls (p = .022), while its cumulative incidence was 90% (95% confidence interval [CI]: 78%-100%) with eltrombopag versus 67.5% (95% CI: 57%-78%) for controls (p = .014). Number of platelet transfusions received, overall survival, progression-free survival, GVHD rate, relapse rate, and non-relapse mortality were similar between groups. Overall, eltrombopag is safe and improves platelet recovery in patients undergoing haplo-HSCT with bone marrow graft and PCy.
引用
- Ahmed S, Bashir Q, Bassett RL, et al. Eltrombopag improves platelet engraftment after haploidentical bone marrow transplantation: Results of a Phase II study. Am J Hematol. 2024. PMID: 38314663. doi:10.1002/ajh.27233
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。